SynthesisFrontiers in neurology2025
Ischemic stroke associated with adenomyosis-related abnormal uterine bleeding: a systematic review of management and outcomes.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adenomyosis is frequently associated with abnormal uterine bleeding (AUB) and anemia. In the setting of arterial stenosis or hypercoagulability, AUB may precipitate ischemic stroke. However, the optimal management strategy remains unclear. Methods: In accordance with PRISMA 2020, we systematically searched PubMed, Web of Science, CNKI, and Wanfang from inception to November 20, 2024, without language restrictions. Eligible studies were human case reports or case series that described adenomyosis-associated ischemic stroke with extractable data on management and outcomes. Data extraction was performed independently by two reviewers, and risk of bias was assessed using the JBI tool. A descriptive synthesis was conducted, and Fisher's exact tests were applied where appropriate. Results: Eighteen studies involving 24 patients fulfilled the inclusion criteria. Among these patients, 66.7% experienced stroke onset during menstruation, 85.7% presented with anemia, and more than 95% showed elevated CA125 and D-dimer levels. Stroke recurrence occurred in 55.6% of patients who received conservative management, compared with 0% of those who underwent hysterectomy (Fisher's exact p ≈ 0.005). In menstruation-related cases managed conservatively, the recurrence rate reached 83.3%. Conclusion: Current evidence indicates that rapid uterine hemostasis may facilitate timely initiation of antithrombotic therapy and thereby reduce recurrence risk in adenomyosis-associated stroke. Surgical management, particularly hysterectomy, appears more effective than conservative therapy in carefully selected high-risk patients. Larger prospective studies are needed to confirm these findings and to refine management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.